Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
Phase 3b trial data show lebrikizumab improves hand and foot atopic dermatitis, giving clinicians trial-based evidence in a hard-to-treat, functionally burdensome phenotype.
Topic
Phase 3b Trial
Topic